NTLA is trading 4.4% up now at $16.73 as investors continue to respond to positive Phase 3 lonvo-z data and significant FDA milestones.

  • The company has made substantial regulatory progress, including a rolling BLA submission and the lifting of clinical holds on key nex-z trials.
  • Analysts highlight Intellia’s strong clinical momentum and late-stage pipeline, with focus shifting toward potential 2027 U.S. launch plans.